Patient Voice, • 9/19/25 Decentralized by Design: Operationalizing Hybrid Rare Disease Trials Previous How to Accelerate the Adoption of Decentralized Trials for Rare Disease Indications Next Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials You Might Also Like Closing Panel: Beyond “One Disease At a Time”: Platform Approaches to Accelerate Gene Therapy Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies
Patient Voice, • 9/19/25 Decentralized by Design: Operationalizing Hybrid Rare Disease Trials Previous How to Accelerate the Adoption of Decentralized Trials for Rare Disease Indications Next Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials You Might Also Like Closing Panel: Beyond “One Disease At a Time”: Platform Approaches to Accelerate Gene Therapy Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies
